GEN-1124

GEN-1124 is a novel small molecule drug developed as a targeted anti-inflammatory and endothelial-stabilizing therapy. It acts as a dual signal modulator by selectively destabilizing the p38α mitogen activated protein kinase (MAPK14): MAPK activated protein kinase 2 (MK2) complex, without inhibiting p38 catalytic activity or ablating downstream signaling. This unique mechanism allows for modulation of critical inflammatory pathways while minimizing off-target effects, resulting in anti-inflammatory, endothelial-stabilizing, and lung-protective properties. GEN-1124 is being developed primarily for the treatment of acute respiratory distress syndrome (ARDS), with ongoing Phase 2 clinical trials evaluating its safety and tolerability in this indication[2][5][3]. The drug was originally discovered at the University of Maryland, Baltimore and is being developed by GEn1E Lifesciences[2][5].